-
Mashup Score: 3Outcomes of Orelabrutinib in Relapsed or Refractory Marginal Zone Lymphoma | Blood Cancers Today - 1 month(s) ago
Orelabrutinib induced high rates of response and sustained remission of disease in a cohort of Chinese patients with relapsed or refractory marginal zone lymphoma.
Source: bloodcancerstoday.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3Two Novel Surrogate Markers for Treatment Effect Validated in Extranodal MZL | Blood Cancers Today - 5 month(s) ago
Investigators validated two substitute markers that predicted treatment effect on eight-year progression-free survival among patients with extranodal marginal zone lymphoma.
Source: bloodcancerstoday.comCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 0Tolerability of Zilovertamab and Ibrutinib in Phase 1/2 Trial of MCL - 11 month(s) ago
Hun Ju Lee, MD, discusses the early results of the dose finding and safety study of zilovertamab plus ibrutinib for patients with mantle cell lymphoma as well as chronic lymphocytic leukemia and marginal zone lymphoma.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
The withdrawn approvals of ibrutinib for relapsed/refractory MCL and MZL are likely to have a limited impact on patients, experts say.
Source: Cancer Therapy AdvisorCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Ibrutinib is No Longer Available for Mantle Cell Lymphoma or Marginal Zone Lymphoma in the United States - 1 year(s) ago
AbbVie has withdrawn the indications for previously pretreated patients with mantle cell lymphoma and marginal zone lymphoma.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Ibrutinib is No Longer Available for Mantle Cell Lymphoma or Marginal Zone Lymphoma in the United States - 1 year(s) ago
AbbVie has withdrawn the indications for previously pretreated patients with mantle cell lymphoma and marginal zone lymphoma.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Ibrutinib is No Longer Available for Mantle Cell Lymphoma or Marginal Zone Lymphoma in the United States - 1 year(s) ago
AbbVie has withdrawn the indications for previously pretreated patients with mantle cell lymphoma and marginal zone lymphoma.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Mixed study results for ibrutinib have led the developer to voluntarily withdraw the agent from the United States market for the treatment of mantle cell and marginal zone lymphoma subgroups.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2Update on IMBRUVICA® (ibrutinib) U.S. Accelerated Approvals for Mantle Cell Lymphoma and Marginal Zone Lymphoma Indications | AbbVie News Center - 1 year(s) ago
NORTH CHICAGO, Ill., April 6, 2023 – AbbVie (NYSE: ABBV) announced today the intent to voluntarily withdraw, in the U.S., accelerated IMBRUVICA® (ibrutinib) approvals for patients with the blood cancers mantle cell lymphoma (MCL) who have received at least one prior therapy and with marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based…
Source: news.abbvie.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Medicines and Healthcare products Regulator
Source: www.businesswire.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
🙌 ICYMI: Orelabrutinib, a novel BTKi, induced high rates of response in patients with relapsed or refractory marginal zone lymphoma. #MZL Learn more about the study, led by Lijuan Deng, MD, of @PKU1898, and published in @AjHematology. 📖 https://t.co/bdS7LZdYBb https://t.co/YsUT1YcX0a